Metabolic alterations in meningioma reflect the clinical course.
Aged
Algorithms
Biomarkers, Tumor
/ analysis
Choline
/ metabolism
Cluster Analysis
Disease Progression
Female
Glycine
/ metabolism
Humans
Male
Meningeal Neoplasms
/ chemistry
Meningioma
/ chemistry
Middle Aged
Neoplasm Grading
Nuclear Magnetic Resonance, Biomolecular
Progression-Free Survival
Serine
/ metabolism
Treatment Outcome
Tryptophan
/ metabolism
Meningioma
Tumour metabolism
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
received:
29
09
2020
accepted:
08
02
2021
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Meningiomas are common brain tumours that are usually defined by benign clinical course. However, some meningiomas undergo a malignant transformation and recur within a short time period regardless of their World Health Organization (WHO) grade. The current study aimed to identify potential markers that can discriminate between benign and malignant meningioma courses. We profiled the metabolites from 43 patients with low- and high-grade meningiomas. Tumour specimens were analyzed by nuclear magnetic resonance analysis; 270 metabolites were identified and clustered with the AutoPipe algorithm. We observed two distinct clusters marked by alterations in glycine/serine and choline/tryptophan metabolism. Glycine/serine cluster showed significantly lower WHO grades and proliferation rates. Also progression-free survival was significantly longer in the glycine/serine cluster. Our findings suggest that alterations in glycine/serine metabolism are associated with lower proliferation and more recurrent tumours. Altered choline/tryptophan metabolism was associated with increases proliferation, and recurrence. Our results suggest that tumour malignancy can be reflected by metabolic alterations, which may support histological classifications to predict the clinical outcome of patients with meningiomas.
Sections du résumé
BACKGROUND
BACKGROUND
Meningiomas are common brain tumours that are usually defined by benign clinical course. However, some meningiomas undergo a malignant transformation and recur within a short time period regardless of their World Health Organization (WHO) grade. The current study aimed to identify potential markers that can discriminate between benign and malignant meningioma courses.
METHODS
METHODS
We profiled the metabolites from 43 patients with low- and high-grade meningiomas. Tumour specimens were analyzed by nuclear magnetic resonance analysis; 270 metabolites were identified and clustered with the AutoPipe algorithm.
RESULTS
RESULTS
We observed two distinct clusters marked by alterations in glycine/serine and choline/tryptophan metabolism. Glycine/serine cluster showed significantly lower WHO grades and proliferation rates. Also progression-free survival was significantly longer in the glycine/serine cluster.
CONCLUSION
CONCLUSIONS
Our findings suggest that alterations in glycine/serine metabolism are associated with lower proliferation and more recurrent tumours. Altered choline/tryptophan metabolism was associated with increases proliferation, and recurrence. Our results suggest that tumour malignancy can be reflected by metabolic alterations, which may support histological classifications to predict the clinical outcome of patients with meningiomas.
Identifiants
pubmed: 33648471
doi: 10.1186/s12885-021-07887-5
pii: 10.1186/s12885-021-07887-5
pmc: PMC7923818
doi:
Substances chimiques
Biomarkers, Tumor
0
Serine
452VLY9402
Tryptophan
8DUH1N11BX
Choline
N91BDP6H0X
Glycine
TE7660XO1C
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211Références
Rogers L, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122:4–23.
doi: 10.3171/2014.7.JNS131644
Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
doi: 10.1007/s00401-016-1545-1
Clark VE, et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet. 2016;48:1253–9.
doi: 10.1038/ng.3651
Brastianos PK, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45:285–9.
doi: 10.1038/ng.2526
Pfisterer WK, et al. Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neuro-Oncol. 2008;87:43–50.
doi: 10.1007/s11060-007-9498-9
Gao F, et al. DNA methylation in the malignant transformation of meningiomas. PLoS One. 2013;8:e54114.
doi: 10.1371/journal.pone.0054114
Goutagny S, et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24:184–9.
doi: 10.1111/bpa.12110
Dunn J, et al. Integration and comparison of transcriptomic and proteomic data for meningioma. Cancers (Basel). 2020;12:3270.
Monleón D, et al. Metabolic aggressiveness in benign meningiomas with chromosomal instabilities. Cancer Res. 2010;70:8426–34.
doi: 10.1158/0008-5472.CAN-10-1498
Bender L, et al. Metabolomic profile of aggressive Meningiomas by using high-resolution magic angle spinning nuclear magnetic resonance. J Proteome Res. 2020;19:292–9.
doi: 10.1021/acs.jproteome.9b00521
Serna E, et al. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma. PLoS One. 2013;8:e67291.
doi: 10.1371/journal.pone.0067291
Bosnyák E, et al. Molecular imaging correlates of tryptophan metabolism via the kynurenine pathway in human meningiomas. Neuro-Oncology. 2015;17:1284–92.
doi: 10.1093/neuonc/nov225.38
Zitron IM, Kamson DO, Kiousis S, Juhász C, Mittal S. In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. Cancer Biol Ther. 2013;14:333–9.
doi: 10.4161/cbt.23624
Beckonert O, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2:2692–703.
doi: 10.1038/nprot.2007.376
Hwang T-L. Water Suppression that Works. Excitation sculping using Arbitrary Waveforms and plused fields gradients. J Magn Reson. 1995;112:275–9.
doi: 10.1006/jmra.1995.1047
Heiland DH, et al. The integrative metabolomic-transcriptomic landscape of glioblastome multiforme. Oncotarget. 2017;8:49178–90.
doi: 10.18632/oncotarget.16544
Hao J, et al. Bayesian deconvolution and quantification of metabolites in complex 1D NMR spectra using BATMAN. Nat Protoc. 2014;9:1416–27.
doi: 10.1038/nprot.2014.090
Hastie TJ, Narasimhan B, Tibshirani RJ, Chu G. Predictive analysis of microarrays; 2002. p. 1–41.
McCullagh, P. , Nelder, J. A. Generalized Linear Models. 500 (Chapman & Hall, 1989).
doi: 10.1007/978-1-4899-3242-6
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
doi: 10.1186/1471-2105-9-559
Holtman IR, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun. 2015;3:31.
doi: 10.1186/s40478-015-0203-5
Iancu OD, et al. Cosplicing network analysis of mammalian brain RNA-Seq data utilizing WGCNA and mantel correlations. Front Genet. 2015;6:174.
doi: 10.3389/fgene.2015.00174
Heiland DH, et al. Integrative network-based analysis of magnetic resonance spectroscopy and genome wide expression in Glioblastoma multiforme. Sci Rep. 2016;6:29052.
doi: 10.1038/srep29052
Luo W, Brouwer C. Pathview: an R/bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013;29:1830–1.
doi: 10.1093/bioinformatics/btt285
Rogers CL, et al. Pathology concordance levels for meningioma classification and grading in NRG oncology RTOG trial 0539. Neuro-Oncology. 2016;18:565–74.
doi: 10.1093/neuonc/nov247
Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39:191–8.
doi: 10.1016/j.tibs.2014.02.004
Gut P, Verdin E. The nexus of chromatin regulation and intermediary metabolism. Nature. 2013;502:489–98.
doi: 10.1038/nature12752
Cheng L, Chang I-W, Louis D, Gonzalez G. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor Specimens1. Cancer Res. 1998;58:1825–32.
pubmed: 9581820
Pfisterer WK, et al. Using ex vivo proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas. Neurosurg Focus. 2010;28:E12.
doi: 10.3171/2009.11.FOCUS09216
Pfisterer WK, et al. Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery. 2007;61:1048–59; discussion 1060.
doi: 10.1227/01.neu.0000303201.62123.5c
Gillies RJ, Barry JA, Ross BD. In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Magn Reson Med. 1994;32:310–8.
doi: 10.1002/mrm.1910320306
Preul M, et al. Accurate, nonivasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med. 1996;2:323–5.
doi: 10.1038/nm0396-323
Mishra G, Phatak S, Kakde D. Role of magnetic resonance spectroscopy in classifying MENINGIOMAS with HIST op a THOLOGICAL CORRELA TION. Int J Sci Res. 2018;7:2277–8179.
Mefford IN, Barchas JD. Determination of tryptophan and metabolites in rat brain and pineal tissue by reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1980;180:187–93.
doi: 10.1016/S0378-4347(00)81604-7
Metz R, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67:7082–7.
doi: 10.1158/0008-5472.CAN-07-1872
de Jong RA, et al. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int J Gynecol Cancer. 2011;21:1320–7.
pubmed: 21720257
Sucher R, et al. IDO-mediated tryptophan degradation in the pathogenesis of malignant tumor disease. Int J Tryptophan Res. 2010;3:113–20.
doi: 10.4137/IJTR.S4157
Prendergast G, Cancer C. Why tumours eat tryptophan. Nature. 2011;478:192–4.
doi: 10.1038/478192a